期刊文献+

骨肉瘤组织中MICA、MMP-9和NF-κB蛋白的表达及相关性 被引量:5

Expression of MICA,MMP-9 and NF-κB and their correlation in osteosarcoma
下载PDF
导出
摘要 目的探讨骨肉瘤组织中MHCⅠ类链相关蛋白A(MHC class Ⅰ chain-related A,MICA)、MMP-9和NF-κB的表达及相互间的关系,为研究骨肉瘤组织中MICA蛋白表达和脱落机制提供组织学依据。方法应用免疫组织化学方法检测66例骨肉瘤、11例骨母细胞瘤,8例骨化性纤维瘤和6例正常骨组织中MICA蛋白的表达情况,并检测66例骨肉瘤组织中MMP-9和NF-κB蛋白的表达情况。结果(1)MICA蛋白在骨肉瘤组织、骨母细胞瘤、骨化性纤维瘤和正常骨组织的表达率分别为51.6%(34/66)、9%(1/11)、0(0/8)、0(0/6),骨肉瘤组织中MICA表达与骨母细胞瘤(P=0.01)、骨化性纤维瘤(P<0.01)和正常骨组织(P<0.05的差异有显著性。(2)骨肉瘤组织中MMP-9和NF-κB表达率分别为55%(36/66)和73%(48/66);NF-κB与MICA(r=0.373,P<0.01)和MMP-9(r=0.536,P<0.01)的表达呈正相关关系。结论MICA蛋白可作为骨肉瘤诊断的分子标志物;NF-κB可能参与MICA蛋白表达和脱落的分子机制,NF-κB可作为骨肉瘤免疫治疗的候选靶点。 Purpose To investigate the mechanism of the expression and shedding of MHC class [ chain - related A ( MICA), and the relationship between MICA, MMP-9 and NF-κB expression in osteosarcoma. Methods MICA expression was examined in 66 cases of osteosareoma, 11 osteoblastoma, 8 ossifying fibroma and 6 normal bone tissues by immunohistochemistry, in which the expression of MMP-9 and NF-κB were also evaluated in the osteosarcoma cases. Results ( 1 ) The expression rates of MICA protein in osteosarcoma, osteoblastoma, ossifying fibrnma and normal bone tissues were 51.6% (34/66), 9% ( 1/11 ), 0 (0/8) and 0 (0/6), respectively. Up-regulation of MICA expression was found in osteosarcoma, compared with osteoblastoma (P = 0. 01 ), ossifying fibroma (P 〈 0. 01 ) and normal bone tissues (P〈0. 05). (2) MMP-9 and NF-κB were detected in 55% (36/66) and 73% (48/66) of osteosarcoma, respectively. NF-κB expression increased with elevated expression of MICA ( r = O. 373, P 〈 0. 01 ) and MMP-9 ( r = 0. 536, P 〈 0. 01 ). Conclusions MICA protein is a useful molecular marker for the diagnosis of osteosarcoma; NF-κB may play a role in the molecular mechanism of the expression and shedding of MICA protein in the osteosarcoma, and it may be a putative target for immunotherapy in osteosarcoma.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2009年第3期270-273,共4页 Chinese Journal of Clinical and Experimental Pathology
基金 国家自然科学基金面上项目资助(No30300354)
关键词 骨肉瘤 MHCⅠ类链相关蛋白A MICA MMP-9 NF-ΚB osteosarcoma MHC class I chain-related A MICA MMP-9 NF-κB
  • 相关文献

参考文献5

二级参考文献37

  • 1张天泽 李树玲.新编常见恶性肿瘤诊治规范-乳腺癌分册[M].北京:北京医科大学、中国协和医科大学联合出版社,1999.27.
  • 2La Casse EC, Baird S, Korneluk RG, et al. The inhibitors of apoptosis (IPAs) and their emerging role in cancer. Oncogene, 1998, 17:3247- 3259
  • 3Wang CY, Mayo MW, Korneluk RG, et al. NF- kappa B Antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to Suppress Caspase-8 Activation. Science, 1998, 281(5383):1680-1683
  • 4Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res, 1998, 58:5071-5074
  • 5Adida C, Crotty PL, Mc Grath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol, 1998, 152:43-49
  • 6Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and caspase-7.Biochemistry, 2001, 40:1117 -1123
  • 7Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature, 1997, 388:300-304
  • 8Mayo MW, Baldwin AS. The transcription factor NF-kappa B: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta, 2000, 1470:M55-62
  • 9[1]Wang CY,Mayo MW,Korneluk RG,et al.NF-kappa B Antiapoptosis:Induction of TRAF1 and TRAF2 and c-IAP1and c-IAP2 to Suppress Caspase-8 Activation.Science,1998,281 (5383):1680~1683
  • 10[2]Suzuki A,Kawano H,Hayashida M,et al.Survivin initiates cell cycle extry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation.Oncogene,2000,19(7865):3225 ~ 3234

共引文献25

同被引文献72

  • 1李健,杜芳,齐义军,郭涛,冯常炜,秦豫培,何欣,范宗民,高珊珊,郭花芹,刘宾,张延瑞,李吉林,焦新英,王立东.食管癌及癌前病变中NF-κB p65/p50蛋白的表达[J].临床与实验病理学杂志,2006,22(5):560-562. 被引量:17
  • 2Diefanbach A,Jensen E R,Jamleson A M,et al.Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity[J].Nature,2001,413(6852):165-71.
  • 3Mochizuki S,Okada Y.ADAMs in cancer cell proliferation and progression[J].Cancer Sci,2007,98(5):621-8.
  • 4Fromowitz F B,Viola M V,Chao S,et al.RasP21expression in the progression of breast cancer[J].Hum Pathol,1987,18(12):1268-75.
  • 5Bauer S,Groh V,Wu J,et al.Activation of NK cells and T cells by NKG2D,a receptor for stress inducible MICA[J].Science,1999,285(5428):727-9.
  • 6Raffaghello L,Prigione I,Airoldi I,et al.Downregulation and /or release of NKG2D ligands as immune evasion strategy of human neuroblastom[J].Neoplasia,2004,6(5):558-68.
  • 7Groh V,Wu J,Yee C,et al.Tumour-derived soluble MIC ligands impair expression of NKG2D and T cell activation[J].Nature,2002,419(6908):679-80.
  • 8Salih H R,Rammensee H G,Steinle A.Down-regulation of MICA on human tumors by proteolytic shedding[J].J Immunol,2002,169(8):4098-102.
  • 9Lendeckel U,Kohl J,Arndt M,et al.Increased expression of ADAM family members in human breast cancer and breast cancer cell lines[J].Cancer Res Clin Oncol,2005,131(1):41-8.
  • 10Kohga K,Takehara T,Tatsumi T,et al.Anticancer chemotherapy inhibits MHC class Ⅰ-related chain.A ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma[J].Cancer Res,2009,69(20):8050-7.

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部